When researchers examined Ewing sarcoma across the country, they found a gap that should not exist. Patients in metropolitan areas had a 36% lower risk of death over time than those in non-metropolitan regions, and the median rural patient survived roughly ten months less than their urban counterpart, not because their cancer was any different but because of where they happened to live. Ten months is the geographic lottery translated into the only currency that finally matters, which is time alive.
The mechanism is the one this whole month keeps uncovering. Rural patients face longer distances to care, fewer specialists nearby, more delay, and steeper practical barriers to reaching the high-volume centers that treat Ewing sarcoma best, and while each of those frictions is survivable on its own, stacked together over the course of a hard cancer they add up to months of lost life. It is worth being precise about what this is and is not: it is not evidence that rural patients are somehow sicker, or that their tumors are more aggressive, but evidence that access, how far you must go, how easily you can get there, how quickly you are seen, is itself a treatment variable, and improving the access closes the gap.
That, as grim as the underlying numbers are, is actually the hopeful part, because a survival gap written into biology would be a wall, whereas a survival gap written into distance and cost is a problem with a solution. The solution happens to be exactly the kind of thing a fund like ours exists to provide, getting rural patients to the centers that give them their best odds. Ten months should never come down to a zip code, and that it currently does is a failure we can help fix.